Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

bausch health ireland limited - rokuronio bromidas - injekcinis ar infuzinis tirpalas - 10 mg/ml - rocuronium bromide

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

septodont - artikaino hidrochloridas/adrenalinas - injekcinis tirpalas - 40 mg/5 µg/ml - articaine, combinations

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

septodont - artikaino hidrochloridas/adrenalinas - injekcinis tirpalas - 40 mg/10 µg/ml - articaine, combinations

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

abbvie sia - sevofluranas - įkvepiamieji garai (skystis) - 250 ml - sevoflurane

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

warszawskie zakłady farmaceutyczne polfa s.a. - bupivakainas - injekcinis tirpalas - 5 mg/ml - bupivacaine

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

ratiopharm gmbh - doksiciklinas - tabletės - 100 mg - doxycycline

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

santen oy - timololis/pilokarpino hidrochloridas - akių lašai (tirpalas) - 5 mg/20 mg/ml - timolol, combinations

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

cheplapharm arzneimittel gmbh - betaksololio hidrochloridas - plėvele dengtos tabletės - 10 mg; 20 mg - betaxolol

Den europeiske union - litauisk - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurija, paroksizminis - selektyvūs imunosupresantai - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Den europeiske union - litauisk - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinoma, nesmulkiųjų ląstelių skausmas - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.